1786.TW
SciVision Biotech Inc. [1786.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1786.TW Stock Summary
Top 10 Correlated ETFs
1786.TW
Top 10 Correlated Stocks
1786.TW
In the News
1786.TW Financial details
Company Rating
Strong Buy
Market Cap
7.35B
Income
177.9M
Revenue
712.99M
Book val./share
24.02
Cash/share
11.87
Dividend
1.98
Dividend %
2.58%
Employees
64
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
30.79
Forward P/E
-
PEG
12.67
P/S
7.44
P/B
3.26
P/C
8.76
P/FCF
24.26
Quick Ratio
5.2
Current Ratio
5.77
Debt / Equity
0.21
LT Debt / Equity
-
-
-
EPS (TTM)
2.66
EPS next Y
-
EPS next Q
-
EPS this Y
24.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
7.65%
Revenue last 5Y
10.24%
Revenue Q/Q
-1.38%
EPS Q/Q
-28.4%
-
-
-
-
SMA20
19.77%
SMA50
41.78%
SMA100
39.27%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
11%
ROC
0.1%
Gross Margin
70%
Oper. Margin
31%
Profit Margin
25%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
67.1-119.0
52W High
-12.61%
52W Low
+55.22%
RSI
54.82
Rel Volume
1.54
Avg Volume
873.44K
Volume
1.35M
Perf Week
-0.95%
Perf Month
15.3%
Perf Quarter
39.04%
Perf Half Y
43.85%
-
-
-
-
Beta
0.635
-
-
Volatility
2.09%, 9.26%
Prev Close
-3.26%
Price
104
Change
-2.8%
1786.TW Financial Performance
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.42 | 1.82 | 2.75 | 3.07 | 3 | |
| Net income per share | 0.45 | 0.5 | 0.77 | 0.81 | 0.58 | |
| Operating cash flow per share | 0.55 | 0.67 | 0.82 | 1.35 | 1.21 | |
| Free cash flow per share | 0.42 | 0.61 | 0.76 | 1.29 | 1.17 | |
| Cash per share | 10.18 | 10.8 | 11.56 | 10.81 | 11.87 | |
| Book value per share | 22.83 | 23.86 | 22.67 | 23.62 | 24.02 | |
| Tangible book value per share | 22.79 | 23.83 | 22.63 | 23.62 | 24.02 | |
| Share holders equity per share | 22.83 | 23.86 | 22.67 | 23.62 | 24.02 | |
| Interest debt per share | 6.32 | 5.8 | 5.58 | 5.26 | 5.17 | |
| Market cap | 3.59B | 4.36B | 6.03B | 5.68B | 5.18B | |
| Enterprise value | 3.42B | 4.14B | 5.72B | 5.37B | 5.02B | |
| P/E ratio | 30.35 | 33.22 | 29.45 | 26.01 | 32.93 | |
| Price to sales ratio | 22.44 | 36.18 | 32.91 | 27.56 | 25.49 | |
| POCF ratio | 97.74 | 97.5 | 109.76 | 62.6 | 63.43 | |
| PFCF ratio | 130.16 | 107.43 | 119.27 | 65.47 | 65.32 | |
| P/B Ratio | 2.37 | 2.76 | 3.99 | 3.58 | 3.18 | |
| PTB ratio | 2.37 | 2.76 | 3.99 | 3.58 | 3.18 | |
| EV to sales | 21.37 | 34.39 | 31.21 | 26.04 | 24.68 | |
| Enterprise value over EBITDA | 62.86 | 69.26 | 88.82 | 59.53 | 74.83 | |
| EV to operating cash flow | 93.08 | 92.68 | 104.09 | 59.13 | 61.44 | |
| EV to free cash flow | 123.95 | 102.12 | 113.12 | 61.84 | 63.26 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Debt to equity | 0.28 | 0.24 | 0.24 | 0.22 | 0.21 | |
| Debt to assets | 0.2 | 0.18 | 0.17 | 0.16 | 0.16 | |
| Net debt to EBITDA | -3.15 | -3.6 | -4.83 | -3.49 | -2.43 | |
| Current ratio | 6.88 | 7.59 | 3.63 | 5.77 | 6.92 | |
| Interest coverage | 16.07 | 19.39 | 22.41 | 38.18 | 27.95 | |
| Income quality | 1.01 | 1.07 | 1.18 | 1.25 | 1.65 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 0 | 0 | 2.44 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.15 | 0.11 | 0.11 | 0.11 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.05 | 0.07 | 0.1 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.25 | -0.09 | -0.08 | -0.04 | -0.03 | |
| Capex to revenue | -0.06 | -0.03 | -0.02 | -0.02 | -0.01 | |
| Capex to depreciation | -0.59 | -0.26 | -0.28 | -0.25 | -0.15 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.14 | 16.31 | 19.8 | 20.79 | 17.72 | |
| ROIC | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Return on tangible assets | 0.01 | 0.02 | 0.02 | 0.03 | 0.02 | |
| Graham Net | 3.28 | 4.51 | 3.49 | 4.83 | 5.87 | |
| Working capital | 752.95M | 798.6M | 726.63M | 803.22M | 858.92M | |
| Tangible asset value | 1.51B | 1.58B | 1.51B | 1.58B | 1.62B | |
| Net current asset value | 293.73M | 374.83M | 315.38M | 410.1M | 470.24M | |
| Invested capital | 0.28 | 0.24 | 0.24 | 0.22 | 0.21 | |
| Average receivables | 98.99M | 108.31M | 121.13M | 143.48M | 131.43M | |
| Average payables | 11.57M | 9.23M | 5.86M | 2.42M | 4.18M | |
| Average inventory | 96.69M | 96.61M | 96.25M | 94.4M | 90.44M | |
| Days sales outstanding | 62.01 | 79.6 | 66.68 | 66.01 | 49.45 | |
| Days payables outstanding | 19.44 | 19.24 | 5.32 | 2.48 | 12.72 | |
| Days of inventory on hand | 187.22 | 220.29 | 157.14 | 144.06 | 164.55 | |
| Receivables turnover | 1.45 | 1.13 | 1.35 | 1.36 | 1.82 | |
| Payables turnover | 4.63 | 4.68 | 16.92 | 36.29 | 7.08 | |
| Inventory turnover | 0.48 | 0.41 | 0.57 | 0.62 | 0.55 | |
| ROE | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Capex per share | -0.14 | -0.06 | -0.07 | -0.06 | -0.03 |
1786.TW Frequently Asked Questions
What is SciVision Biotech Inc. stock symbol ?
SciVision Biotech Inc. is a TW stock and trading under the symbol 1786.TW
What is SciVision Biotech Inc. stock quote today ?
SciVision Biotech Inc. stock price is $104 today.
Is SciVision Biotech Inc. stock public?
Yes, SciVision Biotech Inc. is a publicly traded company.
Company Profile
- Volume Average 873.44K
- Market Capitalization 7.35B
- Employee 64
- CEO Tai Xian Han
- Headquarters Kaohsiung,TW
- IPO Date 2013-03-12
-
Website
https://www.scivision.com.tw 
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.
